Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry

Southern Illinois D-Methionine Noise-Induced Hearing Loss Study

Also known as: D-Methionine, D-methionine oral liquid suspension, D-Met, NCT02903355

Institution-led study

Primary source

Sponsor / Institution

Institution-led study

Program Type

Therapeutic

Modality

Small Molecule

Stage

Phase 3

Status

Discontinued

Target Gene

—

Route / Mode

Oral liquid suspension

Confidence

84%

Status Confidence

Status needs checking

Evidence Strength

Needs more support

Last Reviewed

2026-06-10

Geography

United States

Population

adult, noise-induced

Trial IDs

Mechanism

Terminated Phase 3 academic study of oral D-methionine liquid suspension versus placebo to reduce noise-induced hearing loss.

Indications

Hearing Loss Noise-Induced Hearing Loss

Notes

Verified as a terminated academic Phase 3 NIHL prevention study, not an active commercial program.

Evidence & Sources

1 structured sources

clinicaltrials

Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...

IDs: NCT02903355

Open

Key Events

2013-09-01

Registry lists start for D-methionine NIHL Phase 3 study

2017-12-01

Registry lists actual termination/completion date for D-methionine NIHL study

Clinical Trials (1)

NCT02903355

Data Checks

institution-led-studyregistry-only-evidencehistorical-studygeneric-repurposing-study

Related Programs

Otarmeni by Regeneron

Company: Regeneron Pharmaceuticals · Gene Therapy · Approved

PEDMARK by Fennec Pharmaceuticals

Company: Fennec Pharmaceuticals · Small Molecule · Marketed

AK-OTOF by Eli Lilly and Akouos

Company: Eli Lilly and Company · Gene Therapy · Phase 2

SENS-401 (Arazasetron) by Sensorion

Company: Sensorion · Small Molecule · Phase 2

SENS-501 by Sensorion

Company: Sensorion · Gene Therapy · Phase 1/2

Rincell-1 by Rinri Therapeutics

Company: Rinri Therapeutics · Cell Therapy · Phase 1/2